Concepedia

Rucaparib Therapy

Rucaparib Therapy is a pharmacotherapeutic intervention involving the administration of rucaparib, a selective poly(ADP-ribose) polymerase (PARP) inhibitor, to induce synthetic lethality in tumor cells with homologous recombination repair deficiencies, particularly those harboring BRCA1/2 mutations, within the context of advanced ovarian cancer treatment.

168

Publications

14.7K

Citations

1.3K

Authors

558

Institutions

Publications per year

2017–2026

130

Parents

Publications

168

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

, , +12

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

, , +12

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-yin N. Huang, Amèlie Renaud et al. · Molecular Cancer Therapeutics · 2013 · 758 citations · Full text

, , +15

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration

Wassim Abida, Akash Patnaik, David Campbell et al. · Journal of Clinical Oncology · 2020 · 678 citations · Full text

, , +17

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Yuqiao Shen, Farah Rehman, Ying Feng et al. · Clinical Cancer Research · 2013 · 487 citations · Full text

, , +14

1–5 of 168

Authors

1.3K

  1. SG
    Sandra Goble

    Clovis Oncology (United States), United States

    29 publications · 5.1K citations

    21

    h-index

  2. AM
    Amit M. Oza

    Princess Margaret Cancer Centre, Canada

    29 publications · 6.5K citations

    20

    h-index

  3. LM
    Lara Maloney

    Clovis Oncology (United States), United States

    29 publications · 4.8K citations

    20

    h-index

  4. RL
    Robert L. Coleman

    The University of Texas MD Anderson Cancer Center, United States

    25 publications · 6.6K citations

    18

    h-index

  5. DM
    David M. O’Malley

    The Ohio State University, United States

    26 publications · 6.6K citations

    18

    h-index

1–5 of 1.3K

Institutions

558

  1. Clovis Oncology (United States)

    Boulder, United States

    33 h-index

    269 publications

    62.6K citations

  2. University College London

    London, United Kingdom

    23 h-index

    70 publications

    52.8K citations

  3. Memorial Sloan Kettering Cancer Center

    New York, United States

    22 h-index

    36 publications

    8.5K citations

  4. University of Washington

    Seattle, United States

    22 h-index

    44 publications

    10K citations

  5. Vall d'Hebron Hospital Universitari

    Barcelona, Spain

    21 h-index

    32 publications

    6.7K citations

  6. Princess Margaret Cancer Centre

    Toronto, Canada

    21 h-index

    33 publications

    8.9K citations

  7. The University of Texas MD Anderson Cancer Center

    Houston, United States

    20 h-index

    34 publications

    7.2K citations

  8. Institut Gustave Roussy

    Villejuif, France

    19 h-index

    42 publications

    7K citations

1–8 of 558

Venues

  1. Journal of Clinical Oncology

    25 publications · 1.9K citations

    17

    h-index

  2. Gynecologic Oncology

    9 publications · 490 citations

    9

    h-index

  3. Molecular Cancer Therapeutics

    MCT · 7 publications · 1.1K citations

    8

    h-index

  4. Annals of Oncology

    7 publications · 264 citations

    7

    h-index

  5. Cancer Research

    6 publications · 351 citations

    6

    h-index

1–5